American Journal of Cardiology
Volume 101, Issue 12, Supplement , Pages S51-S57 , 16 June 2008

Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines

  • Michael H. Davidson, MD

      Affiliations

    • Preventive Cardiology Center, University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    • Radiant Research, Chicago, Illinois, USA
    • Corresponding Author InformationAddress for reprints: Michael H. Davidson, MD, Preventive Cardiology Center, University of Chicago Pritzker School of Medicine, 515 North State Street, Suite 2700, Chicago, Illinois 60610.
    • ,
  • Marshall A. Corson, MD

      Affiliations

    • Department of Medicine, University of Washington, Seattle, Washington, USA
    • ,
  • Mark J. Alberts, MD

      Affiliations

    • Department of Neurology, Northwestern University Medical School, Chicago, Illinois, USA
    • ,
  • Jeffrey L. Anderson, MD

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, Utah, USA
    • ,
  • Philip B. Gorelick, MD

      Affiliations

    • Department of Neurology and Rehabilitation, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA
    • ,
  • Peter H. Jones, MD

      Affiliations

    • Baylor Lipid and Atherosclerosis Clinic, Baylor College of Medicine, Houston, Texas, USA
    • ,
  • Amir Lerman, MD

      Affiliations

    • Division of Cardiovascular Disease, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    • ,
  • Joseph P. McConnell, PhD

      Affiliations

    • Departments of Cardiovascular Diseases and Laboratory Medicine, Immunochemical Core Laboratory, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    • ,
  • Howard S. Weintraub, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, New York University Medical Center, New York City, New York, USA.

References 

  1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421II-30–II-31
  2. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  3. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al Markers of inflammation and cardiovascular disease: application to clinical and public health practice (A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association). Circulation. 2003;107:499–511
  4. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation. 2006;113:2363–2372
  5. Garza CA, Montoir VM, McConnell JP, Somers VK, Jullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007;82:159–165
  6. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837–842
  7. Koenig W, Khuseyinova N, Löwel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany (MONICA-Augsburg). Circulation. 2004;110:1903–1908
  8. May HT, Horne BD, Anderson JL, Wolfert RL, Muhlestein JB, Renlund DG, et al. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J. 2006;152:997–1003
  9. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312–318
  10. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke. 2006;37:1583–1633
  11. Sever PS, Dahlof B, Poulter NR, Wedel H, Bevers G, Caulfield M, et al Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003;361:1149–1158
  12. Coull BM. Statin therapy after acute ischemic stroke in the heart protection study: is the role in recurrent stroke prevention now defined?. Stroke. 2004;35:2233–2234
  13. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:684–696
  14. Persson M, Hedblad B, Nelson J, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol. 2007;27:1411–1416
  15. Carlquist JF, Muhlestein JB, Anderson JL. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn. 2007;7:511–517
  16. Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008;101(suppl 12A):23F–33F
  17. Moldoveanu E, Tanaseanu C, Tanaseanu S, Kosaka T, Manea G, Marta DS, et al. Plasma markers of endothelial dysfunction in type 2 diabetics. Eur J Intern Med. 2006;17:38–42
  18. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, März W. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab. 2004;89:1153–1159
  19. Corsetti JP, Ryan D, Moss AJ, Rainwater DL, Zareba W, Sparks CE. Glycoprotein 1bα polymorphism T145M, elevated lipoprotein-associated phospholipase A2, and hypertriglyceridemia predict risk for recurrent coronary events in diabetic post-infarction patients. Diabetes. 2007;56:1429–1435
  20. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26:137–144
  21. McHugh VL, Barnhart SI, Schaper AM, Mathiason MA, Akosah KO. Improving risk prediction in primary prevention: the role of carotid ultrasound, hs-CRP and Lp-PLA2. Presented at the American Heart Association Epidemiology and Vascular Biology Annual Meeting; Phoenix, Arizona, March 2–5, 2006. Abstract P107.
  22. Winkler K, Hoffman MM, Winkelmann BR, Friedrich I, Schafer G, Seelhorst U, et al. Lipoprotein-associated phospholipase A2 predicts 5-year mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem. 2007;53:1440–1447
  23. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Stobos N, Fabunmi RP, et al Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109:672–693
  24. Rajogapalan S, Kariisa M, Brook R, Dellegrottaglie S, Hinderliter AS, Zhang X, Chang S, Kiser M, Eisele G, Finkelstein F, et al. Lipoprotein-associated phospholipase A2 in chronic kidney disease: results from the RRI-CKD Study. Presented at the American College of Cardiology 55th Annual Scientific Sessions Meeting; March 11–14, 2006; Atlanta, Georgia. Abstract 854-7.
  25. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function and hemodynamic stress (KAROLA). Arterioscler Thromb Vasc Biol. 2006;26:1586–1593
  26. Ridker PM, Cannon CP, Morrow D, Rifai N, McCabe CH, Pfeffer MA, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28
  27. Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR, et al. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol. 2006;9:138–143
  28. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol. 2006;26:2517–2522
  29. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  30. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  31. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  32. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  33. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  34. Sisson SD, Rice TN, Hughes MT. Physician knowledge of national cholesterol guidelines before and after an interactive curriculum. Am J Cardiol. 2007;99:1234–1235
  35. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med. 2006;166:2073–2080
  36. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516
  37. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies of 55,000 vascular deaths. Lancet. 2007;370:1829–1839

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9149(08)00716-9

doi: 10.1016/j.amjcard.2008.04.019

American Journal of Cardiology
Volume 101, Issue 12, Supplement , Pages S51-S57 , 16 June 2008

Article Tools

* Image Usage & Resolution